FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W229748687> ?p ?o ?g. }

• W229748687 endingPage "813" @default.
• W229748687 startingPage "807" @default.
• W229748687 abstract "This multicentre, double-blind, double-dummy, randomised trial was designed to compare the efficacy and safety of single intravenous doses of dolasetron mesilate and granisetron in the prevention of acute emesis and nausea due to high-dose (> or = 80 mg/m2) cisplatin. Single intravenous doses of 1.8 or 2.4 mg/kg of dolasetron mesilate or 3 mg of granisetron hydrochloride were administered in a volume of 50 ml over a 5-min period, beginning 30 min prior to cisplatin (> or = 80 mg/m2) administration. The number and timing of emetic episodes, time to administration of escape anti-emetic medication, severity of nausea by visual analogue scale (VAS), and safety were monitored for 24 h after the start of cisplatin-containing chemotherapy. Investigators' evaluations of overall efficacy and patients' satisfaction with therapy were recorded at the end of the 24-h study period. Of the 474 patients evaluable for efficacy, complete responses were achieved by 54, 47 and 48% of patients given dolasetron mesilate 1.8 mg/kg, dolasetron mesilate 2.4 mg/kg and granisetron, respectively. Statistically, treatment groups had comparable complete and complete plus major responses, times to first emesis, and use of escape medication; patient maximum nausea severity and treatment satisfaction ratings; and physician nausea severity and overall efficacy assessments. For the majority of efficacy endpoints, 1.8 mg/kg dolasetron mesilate produced numerically superior responses compared with the 2.4 mg/kg dose. Gender and prior chemotherapy were significant predictors of complete response; males and chemotherapy-naive patients had higher responses. The overall incidences of adverse events were comparable among the treatment groups; headache and diarrhoea were most common. In conclusion, 1.8 and 2.4 mg/kg of dolasetron mesilate and granisetron (3 mg) were equally effective in preventing nausea and vomiting induced by highly emetogenic cisplatin-containing chemotherapy. In addition, because no additional benefit was observed with 2.4 mg/kg of dolasetron mesilate and numerically greater responses were observed with the 1.8 mg/kg dose, the lower dose of 1.8 mg/kg is optimal for further clinical development." @default.
• W229748687 created "2016-06-24" @default.
• W229748687 creator A5004545253 @default.
• W229748687 creator A5016158055 @default.
• W229748687 creator A5024260899 @default.
• W229748687 creator A5028299314 @default.
• W229748687 creator A5060539348 @default.
• W229748687 creator A5063935752 @default.
• W229748687 creator A5075795161 @default.
• W229748687 creator A5084749518 @default.
• W229748687 creator A5086083902 @default.
• W229748687 creator A5091727687 @default.
• W229748687 date "1996-05-01" @default.
• W229748687 modified "2023-10-06" @default.
• W229748687 title "A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy" @default.
• W229748687 cites W1917087166 @default.
• W229748687 cites W1975217469 @default.
• W229748687 cites W1995925329 @default.
• W229748687 cites W1997373870 @default.
• W229748687 cites W2003432957 @default.
• W229748687 cites W2006520202 @default.
• W229748687 cites W2029032003 @default.
• W229748687 cites W2029730896 @default.
• W229748687 cites W2047708283 @default.
• W229748687 cites W2050034405 @default.
• W229748687 cites W2052109081 @default.
• W229748687 cites W2053004350 @default.
• W229748687 cites W2071127529 @default.
• W229748687 cites W2078029775 @default.
• W229748687 cites W2126516096 @default.
• W229748687 cites W2149919960 @default.
• W229748687 cites W2153494490 @default.
• W229748687 cites W2160101513 @default.
• W229748687 cites W2194618417 @default.
• W229748687 cites W2264441265 @default.
• W229748687 cites W2295898466 @default.
• W229748687 cites W2300669756 @default.
• W229748687 cites W2315764977 @default.
• W229748687 cites W2327612061 @default.
• W229748687 cites W2338394838 @default.
• W229748687 cites W2783843108 @default.
• W229748687 cites W4233583951 @default.
• W229748687 cites W77070658 @default.
• W229748687 doi "https://doi.org/10.1016/0959-8049(96)00025-1" @default.
• W229748687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9081358" @default.
• W229748687 hasPublicationYear "1996" @default.
• W229748687 type Work @default.
• W229748687 sameAs 229748687 @default.
• W229748687 citedByCount "50" @default.
• W229748687 countsByYear W2297486872012 @default.
• W229748687 countsByYear W2297486872013 @default.
• W229748687 countsByYear W2297486872014 @default.
• W229748687 countsByYear W2297486872017 @default.
• W229748687 countsByYear W2297486872021 @default.
• W229748687 crossrefType "journal-article" @default.
• W229748687 hasAuthorship W229748687A5004545253 @default.
• W229748687 hasAuthorship W229748687A5016158055 @default.
• W229748687 hasAuthorship W229748687A5024260899 @default.
• W229748687 hasAuthorship W229748687A5028299314 @default.
• W229748687 hasAuthorship W229748687A5060539348 @default.
• W229748687 hasAuthorship W229748687A5063935752 @default.
• W229748687 hasAuthorship W229748687A5075795161 @default.
• W229748687 hasAuthorship W229748687A5084749518 @default.
• W229748687 hasAuthorship W229748687A5086083902 @default.
• W229748687 hasAuthorship W229748687A5091727687 @default.
• W229748687 hasConcept C141071460 @default.
• W229748687 hasConcept C2776694085 @default.
• W229748687 hasConcept C2777452722 @default.
• W229748687 hasConcept C2778239845 @default.
• W229748687 hasConcept C2780580376 @default.
• W229748687 hasConcept C2780852908 @default.
• W229748687 hasConcept C2780884295 @default.
• W229748687 hasConcept C42219234 @default.
• W229748687 hasConcept C71924100 @default.
• W229748687 hasConceptScore W229748687C141071460 @default.
• W229748687 hasConceptScore W229748687C2776694085 @default.
• W229748687 hasConceptScore W229748687C2777452722 @default.
• W229748687 hasConceptScore W229748687C2778239845 @default.
• W229748687 hasConceptScore W229748687C2780580376 @default.
• W229748687 hasConceptScore W229748687C2780852908 @default.
• W229748687 hasConceptScore W229748687C2780884295 @default.
• W229748687 hasConceptScore W229748687C42219234 @default.
• W229748687 hasConceptScore W229748687C71924100 @default.
• W229748687 hasIssue "5" @default.
• W229748687 hasLocation W2297486871 @default.
• W229748687 hasLocation W2297486872 @default.
• W229748687 hasOpenAccess W229748687 @default.
• W229748687 hasPrimaryLocation W2297486871 @default.
• W229748687 hasRelatedWork W2039989837 @default.
• W229748687 hasRelatedWork W2052629648 @default.
• W229748687 hasRelatedWork W2074431992 @default.
• W229748687 hasRelatedWork W2204555883 @default.
• W229748687 hasRelatedWork W2351639907 @default.
• W229748687 hasRelatedWork W2371627609 @default.
• W229748687 hasRelatedWork W2399120251 @default.
• W229748687 hasRelatedWork W2491636352 @default.
• W229748687 hasRelatedWork W2624014703 @default.
• W229748687 hasRelatedWork W4320923492 @default.

• next